Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Atopic Dermatitis
Interventions: omalizumab; Biological
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Familial Amyloid Polyneuropathy, Familial Amyloidosis
Interventions: diflunisal, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York

Conditions: Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
Interventions: Group 1; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Years to 8 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Atopic Dermatitis
Interventions: Trier Social Stress Test (TSST), Landscape Video; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 59 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Intermittent Porphyria
Interventions: recombinant human porphobilinogen deaminase (Porphozym); Drug
Lead sponsor: Zymenex A/S; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Neuroblastoma, Sarcoma
Interventions: Cabozantinib; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Months to 40 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 6
States / cities: Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 3 more

Conditions: MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions: Glycerol Tributyrate; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Urea Cycle Disorders
Interventions: HPN-100, NaPBA; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 4 more

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia
Interventions: clofarabine, cytarabine, filgrastim; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Angelman Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Day to 60 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 6
States / cities: San Diego, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more

Conditions: Cystic Fibrosis
Interventions: Exhaled Breath Condensate; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions: sirolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Granulomatous Disease, Chronic
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more

Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab; Drug
Lead sponsor: Parabilis Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant tablet, Placebo tablet; Drug · Other
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 16 more

Conditions: Malignant Neoplasm
Interventions: ponatinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Sameek Roychowdhury; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Pompe Disease
Interventions: Diaphragm conditioning via phrenic nerve stimulation; Other
Lead sponsor: University of Florida; Other
Eligibility: 2 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Bronchopulmonary Dysplasia
Interventions: MagniXene, hyperpolarized 129Xe MRI; Combination Product
Lead sponsor: Xemed LLC; Industry
Eligibility: Up to 1 Year
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Ciliary Dyskinesia, PCD
Interventions: Exercise, HS pretreatment with Exercise; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anesthesia; Hypothermia, Congenital Heart Disease
Interventions: MRI-safe bore covering; Device
Lead sponsor: Andrew Matisoff; Other
Eligibility: Up to 7 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Urea Cycle Disorder
Interventions: Diagnostic Ultrasound; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Fort Myers, Florida • Miami, Florida + 4 more

Conditions: Chorea, Huntington
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 27 more

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Not listed
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boca Raton, Florida

Search by objective public record fields.

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

The Effect of Diflunisal on Familial Amyloidosis

Collection of Cerebrospinal Fluid in Healthy Children

Stress-induced Scratching in Healthy and AD

Porphozym in the Treatment of Acute Attacks in AIP

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

Characterization of Angelman Syndrome

Breath Condensate Study in Patients With Cystic Fibrosis.

Sirolimus for Autoimmune Disease of Blood Cells

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

FOG-001 in Locally Advanced or Metastatic Solid Tumors

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Response to Diaphragmatic Pacing in Subjects With Pompe Disease

129Xe MRI in Pediatric Population With BPD

Clearance in Primary Ciliary Dyskinesia

Evaluation of a Novel Patient Warming System During MRI

Chronic Liver Disease in Urea Cycle Disorders

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients